Table 2.
Different nanoparticle-based approaches for experimental treatment of sepsis
| S. No. | Formulations | Therapeutic outcome | Reference |
|---|---|---|---|
| 1 | Liposomes loaded ATP or NAD+ | Protect human endothelium from energy failure in cell culture models | Han et al., 2001 |
| 2 | Ciprofloxacin-loaded lipid emulsion | Animal survival improved in LPS-induced sepsis mice model | Mishra, 2011 |
| 3 | Chitosan capped gold nanoparticles | Protective effects against LPS-induced toxicity in rats | Stefan et al., 2013 |
| 4 | Antisense oligonucleotides in pH-sensitive liposomes | LPS-induced production of TNF-α in rats | Ponnappa et al., 2001 |
| 5 | Liposomal dexamethasone | Prophylaxis against LPS-induced lung injuries in rats | Suntres and Shek, 2000 |
| 6 | Curcumin exosomes | Mice treated with exosomal curcumin have much lower mortality than mice treated with an equivalent concentration of liposomal curcumin | Sun et al., 2010 |
| 7 | Minocycline nanoliposomes | Reduction in LPS induces TNF-α by macrophages at lower doses | Liu and Yang, 2012 |
| 8 | Puerarin and curcumin loaded gold nanoparticles | Suppression of LPS-induced inflammation and cytotoxicity in rats | Singh et al., 2013 |
| 9 | Glycyrrhizic acid nanoparticles | Inhibition of LPS-induced inflammatory mediators in 264.7 mouse macrophages | Wang et al., 2013 |
| 10 | Red blood cell-mediated delivery of dexamethasone | Selective inhibition of NF-κB activation and TNF-α production in macrophages | Crinelli et al., 2000 |
| 11 | Ciprofloxacin-bearing cationic nanoemulsions | Reduction in LPS released from E. coli and reduction in cytokine secretion in E. coli-induced peritonitis in rats | Jain et al., 2014 |
| 12 | Parenteral triglyceride-rich emulsions | Have the capacity to inactivate endotoxin in vitro and to prevent death from a lethal dose of endotoxin in animals | Hultin et al., 1995 |
| 13 | Peptoid 7 PEG micelles | LPS neutralization in vivo improves survival in mice with sepsis | Vicent et al., 2010 |